Table 1.
Patient and treatment characteristics.
| ≤100 Gy group | >100 Gy group | P-value | |
|---|---|---|---|
| No. of patients/treated lesions | 40/41 | 50/56 | |
| Sex | 1.00 | ||
| Male | 23 (57.5%) | 29 (58.0%) | |
| Female | 17 (42.5%) | 21 (42.0%) | |
| Age at treatment (years) | 64.3 (40.6–84.9) | 64.2 (38.5–85.8) | 0.54 |
| Primary tumor location | 0.81 | ||
| Colorectal | 30 (75.0%) | 39 (78.0%) | |
| Other gastrointestinal tumor | 3 (7.5%) | 2 (4.0%) | |
| Lung | 3 (7.5%) | 1 (2.0%) | |
| Breast | 1 (2.5%) | 3 (6.0%) | |
| Melanoma | 0 (0%) | 1 (2.0%) | |
| Other | 3 (7.5%) | 4 (8.0%) | |
| Extrahepatic disease | 0.50 | ||
| None | 26 (65.0%) | 35 (70.0%) | |
| Lung | 7 (17.5%) | 9 (18.0%) | |
| Peritoneum | 3 (7.5%) | 1 (2.0%) | |
| Lymph nodes | 2 (5.0%) | 1 (2.0%) | |
| Other | 2 (5.0%) | 4 (8.0%) | |
| Previous treatment | 0.71 | ||
| None | 5 (12.5%) | 5 (10.0%) | |
| Local therapy (surgery, radiotherapy, ablation) | 1 (2.5%) | 3 (6.0%) | |
| Systemic therapy | 31 (77.5%) | 31 (62.0%) | |
| Combination of local and systemic treatment | 3 (7.5%) | 11 (22.0%) | |
| Volumes | |||
| GTV (cm3) | 18.4 (1.3 – 195.0) | 14.5 (1.0 – 157.3) | 0.31 |
| PTV (cm3) | 86.5 (19.0 – 481.6) | 66.0 (18.4 – 400.4) | 0.094 |
| Prescribed dose | |||
| Dose per fraction (Gy) | 12.5 (12.0 – 15.0) | 20.0 (12.0 – 20.0) | <0.001 |
| Total dose (Gy) | 37.50 (36.0 – 45.0) | 60.0 (51.0 – 60.0) | <0.001 |
| Biologically Effective Dose | |||
| BED98% (Gy) | 77.6 (8.1 – 93.1) | 175.2 (103.7 – 355.8) | <0.001 |
| BED2% (Gy) | 143.3 (71.1 – 336.8) | 300.8 (143.6 – 347.5) | <0.001 |
| Relative near-minimum PTV dose (%) | 90.9 (16.0 – 98.84) | 94.6 (40.0 – 98.8) | 0.22 |
Data are reported as number (percent) or median (range) Abbreviations: GTV: gross tumor volume. PTV: planned target volume. BED98% = near minimum BED. BED2% = near-maximum BED.